CHARTER OF THE
SCIENCE AND TECHNOLOGY COMMITTEE
OF THE BOARD OF DIRECTORS
OF NKARTA, INC.

1. **Purpose.** The Science and Technology Committee (the "Committee") is appointed by the Board of Directors (the "Board") of Nkarta, Inc. (the "Company") to assist the Board in its oversight of management's exercise of its responsibilities relating to:

   - the Company's research and development ("R&D") strategy, Chemistry Manufacturing and Controls ("CMC") strategy, clinical and regulatory strategy, and product pipeline;

   - emerging or evolving scientific, technological, medical, or clinical issues of importance to the Company, including as related to achieving the Company's R&D, CMC, clinical and regulatory strategies; and

   - risks associated with the Company's R&D, CMC, clinical and regulatory strategies.

2. **Membership.** The Committee shall be comprised of at least two (2) members of the Board. The members of the Committee shall be appointed by the Board and shall serve until the earlier of their resignation or removal by the Board in its discretion. Each Committee member shall, as determined in the business judgment of the Board, qualify as an "independent director," as such term is defined under the listing standards of The Nasdaq Stock Market LLC ("Nasdaq").

   The members of the Committee shall be appointed by and serve at the discretion of the Board. Committee members may be removed at any time by the Board. The Board will appoint one member of the Committee to serve as the Chairperson of the Committee (or, at the Board's discretion, two members to serve as co-Chairpersons of the Committee).

3. **Specific Responsibilities and Duties**. In addition to the Committee's general tasks and responsibilities described above, the following duties and responsibilities are the specific functions of the Committee, to be performed as the Committee deems necessary or appropriate:

   - Review and monitor progress of the Company's product pipeline, including its preclinical programs and clinical stage assets, and the Company's manufacturing plans.

   - Review, evaluate and assess the overall quality, direction, competitiveness, and effectiveness of the Company's R&D programs and manufacturing processes, and related strategies.

   - Review and discuss with management (i) management's program to identify, assess, manage, and monitor significant technical and clinical risks; and (ii) management's risk management decisions, practices and activities around significant technical and clinical risks.

   - Review management's proposals and advise the Board on potential external investments in science and technology and the scientific, technical, medical, or clinical aspects of potential future business development opportunities.

   - Identify and discuss emerging scientific and clinical trends and advancements relevant to the Company's industry, products, and pipeline, and provide strategic advice to the Board

regarding emerging technologies for building the Company's technological strength, pipeline, and competitive position.

- Review and make recommendations to the Board with respect to the Company's allocation of resources to research, clinical, regulatory and CMC organizations.

- To the extent deemed necessary or appropriate by the Committee, review with management the Company's pre-clinical, translational, and clinical programs, including the design, conduct, and results of clinical trials.

- To the extent deemed necessary or appropriate by the Committee, review with management the Company's manufacturing strategy, manufacturing capabilities, and technical operations.

- Discuss and advise the Board on other matters of scientific, technical, medical, or clinical importance as the Board may designate from time to time.

- Review the Committee's charter annually and submit any recommended changes to the Board.

- Perform such other functions as assigned by law, the Company's charter or bylaws, or the Board.

The Committee's role is one of review and oversight. While the Committee has the responsibilities and powers set forth in this charter, it is not the duty of the Committee to address day-to-day scientific, technical or clinical issues. These are the responsibilities of management.

4. Organization and Operations.

- **Meetings**. The Committee will meet with such frequency, and at such times as its Chairperson, or a majority of the Committee, determines, but not less than quarterly each year. Such meetings, at the Committee's discretion, may be in person, by telephone or video conference, or by unanimous written consent. A special meeting of the Committee may be called by the Chairperson and will be called promptly upon the request of any two Committee members. Unless the Committee or the Board adopts other procedures, the provisions of the Company's bylaws, as in effect from time to time and as applicable to meetings of the Board, will govern meetings of the Committee. A quorum for any meeting of the Committee shall be a majority of the members of the Committee.

- **Minutes and Reports**. Minutes of each meeting will be kept with the regular corporate records. The Committee will periodically report to the Board its findings and actions.

- **Subcommittees**. The Committee has the power to appoint subcommittees, each of which may have (as determined by the Committee) the full power and authority of the Committee; provided, however, that the Committee shall not delegate to a subcommittee any power or authority required by any law or regulation to be exercised by the Committee as a whole. Each such subcommittee shall consist of at least one member of the Committee.

- **Voting.** Each Committee member shall have one vote and actions at meetings must be approved by a majority of the members present.

5. Reliance; Experts; Cooperation.

- **Retention of Outside Advisors**. The Committee may retain at the Company's expense such independent scientific, technical, medical, clinical and other advisors and experts as it deems necessary or appropriate to carry out its duties, including the authority to approve any such outside advisor's fees and other retention terms

- **Reliance Permitted**. In carrying out its duties, the Committee may act in reliance on management, outside advisors and experts, as it deems necessary or appropriate.

- **Participation of Employees and Outside Experts**. The Committee shall have access to the Company's key scientific, technical, and clinical personnel, internal and outside counsel, and anyone else in the Company and may request any officer or employee of the Company or the Company's outside counsel to attend a meeting of the Committee or to meet with any members of, or consultants or advisors to, the Committee.